AstraZeneca (AZN) Tops Q3 EPS by 2c

AstraZeneca (NYSE: AZN) reported Q3 EPS of $1.12, $0.02 better than the analyst estimate of $1.10. Revenue for the quarter came in at $6.23 billion versus the consensus estimate of $5.99 billion.

Updated Guidance

• Total Revenue A low to mid single-digit percentage decline
• Core EPS Towards the favourable end of a low to mid teens percentage decline

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• AeroVironment (AVAV) Tops Q4 EPS by 36c